UK's CelLBxHealth preliminary FY revenue misses its expectations due to deferred contracts

Cellbxhealth

16/01/2026 07:16

Corrects Key Details table to say preliminary FY 2025 revenue was GBP 1.4 mln, not GBP 1.6 mln; adds first bullet for clarification

Overview

Precision CTC intelligence firm posts prelim FY 2025 revenue of about £1.4 mln, below its expectation of £1.6 mln

Company reports preliminary Q4 2025 revenue of about £0.4 mln

Company expects to save £5.9 mln on annualised basis by cost rationalisation measures

Outlook

Company focused on delivery of commercial milestones from qualified 2026/27 sales pipeline of £12.6 mln (risk-weighted at £4.5 mln)

Company expects cost savings of £5.9 mln on annualised basis from restructuring

Result Drivers

SALES CONTRACT DEFERRAL - £0.2 mln in sales contracts deferred to Q1 2026, impacting FY 2025 revenue

COST RATIONALISATION - Co to save £5.9 mln on annualised basis through cost reductions, including headcount reductions

REVISED STRATEGY - Focus on delivery of commercial milestones from qualified 2026/27 sales pipeline valued at £12.6 mln to drive revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
GBP 1.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cellbxhealth PLC is GBP17.00, about 1,600% above its January 15 closing price of GBP1.00

Press Release: ID:nRSP1444Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)